
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
How you talk to and play with your young child can make a big difference in her language ability, even if she has already been referred for evaluation or therapy because of the pediatrician’s concerns about late talking. Here are some recommendations for promoting development of speech.






